Cyfuse Biomedical KK (TSE:4892) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4892 Cyfuse Biomedical KK TSE:4892
59 GF Score
Price 円546.00
GF Value 円2,081.98
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cyfuse Biomedical KK is: High Risk: High uncertainty.

Cyfuse Biomedical KK  (TSE:4892) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cyfuse Biomedical KK Risk Assessment Related Terms

TSE:4892 vs ZTS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyfuse Biomedical KK Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Risk Assessment falls into.


TSE:4892
59GF Score
Cyfuse Biomedical KK TSE:4892
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円546.00 is trading 73.8% below its estimated GF Value™ of 円2,081.98. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for TSE:4892:

  • Risk Assessment:
  • GF Value™: 円2,081.98 vs. price of 円546.00 (73.8% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Other Exchanges 4892:Japan
Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
59GF Score

Get the complete analysis for TSE:4892

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円546.00
Price
円2,081.98
GF Value